Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short-term Investments (2023 - 2025)

Historic Short-term Investments for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $17.3 million.

  • BioLineRx's Short-term Investments fell 1494.32% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year decrease of 1494.32%. This contributed to the annual value of $9.1 million for FY2024, which is 7644.23% down from last year.
  • As of Q3 2025, BioLineRx's Short-term Investments stood at $17.3 million, which was down 1494.32% from $21.0 million recorded in Q2 2025.
  • BioLineRx's 5-year Short-term Investments high stood at $38.7 million for Q4 2023, and its period low was $9.1 million during Q4 2024.
  • Over the past 3 years, BioLineRx's median Short-term Investments value was $21.0 million (recorded in 2025), while the average stood at $22.9 million.
  • Data for BioLineRx's Short-term Investments shows a peak YoY increase of 3401.88% (in 2024) and a maximum YoY decrease of 7644.23% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows BioLineRx's Short-term Investments stood at $38.7 million in 2023, then plummeted by 76.44% to $9.1 million in 2024, then skyrocketed by 89.55% to $17.3 million in 2025.
  • Its last three reported values are $17.3 million in Q3 2025, $21.0 million for Q2 2025, and $17.3 million during Q1 2025.